查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401950

到 2030 年神经刺激的市场预测：按类型、应用和地区分類的全球分析

Neurostimulation Market Forecasts to 2030 - Global Analysis By Type, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球神经刺激市场规模为 62.212 亿美元，预计到 2030 年将达到 133.29 亿美元，预测期内复合年增长率为 11.5%。

使用协调的电或磁脉衝来改变神经系统的活动称为神经刺激。它用于治疗多种神经病变，包括精神疾病、运动障碍和慢性疼痛。此外，神经刺激是一种可逆且可自订的方式来调节神经迴路并减轻相关症状，目前正在研究新的应用，并正在优化现有技术。

据美国疾病管制与预防美国(CDC) 称，北美每年估计花费 500 亿美元用于治疗慢性下背痛。

非侵入性替代方案的增加

由于非侵入性神经刺激方法的发展以及提供非手术方法（例如经颅磁刺激（TMS）和经皮电神经刺激（TENS））的技术进步，这些方法正在获得认可。该方法正在减少患者的被动性和扩大市场范围。这项转变不仅提高了患者的舒适度和安全性，而且还提供了高效、负担得起的微创解决方案，使我们能够在塑造神经刺激疗法和市场的方向方面发挥关键作用。我们正在扩大规模。

高成本

开发、製造和行销神经刺激设备是一个昂贵的过程，需要先进的技术、广泛的研究和监管合规性。专用零件、尖端材料和复杂的製造技术都会导致成本高昂。这些高昂的成本给患者和医疗保健提供者在负担能力和报销方面带来了挑战。因此，高昂的自付费用和缺乏保险覆盖可能会阻碍神经刺激市场的发展。

技术进步

技术创新推动了封闭回路型或自适应神经刺激系统的发展，电极技术、程式设计能力和设备设计不断创新，提高了神经刺激治疗的准确性、有效性和安全性。此外，无线通讯技术的整合可以更好地病患监测并即时调整神经刺激参数。改善患者治疗效果和解决未满足的医疗需求正在推动整个神经刺激治疗市场的发展。

副作用

神经刺激并非对所有神经系统疾病都同样有效，侵入性手术和植入设备固有的风险（例如感染、设备故障和意外副作用）可能会限制患者的安全、性能和可靠性。此外，不利事件可能会损害产品在市场上的声誉，引发监管问题和法律问题，并阻碍其普及。结果，神经刺激市场受到阻碍。

COVID-19 的影响

COVID-19 的爆发对神经刺激市场产生了负面影响，扰乱了製造、供应链和选择性医疗程序。对非必要医疗保健服务的限制、患者就诊的减少以及医疗资源的转移正在推迟神经刺激设备并减少患者的就诊机会。经济不确定性也影响投资和研究经费。因此，这些因素都大大阻碍了市场的拓展。

迷走神经刺激设备部分预计在预测期内将是最大的

迷走神经刺激设备部分估计占最大占有率。这些植入式设备透过刺激迷走神经来运作，迷走神经向大脑发送电脉衝。技术进步、设备小型化以及对神经生理学理解的加深是有助于提高意识的一些创新。对非药物治疗选择的需求和神经系统疾病盛行率的增加正在促进 VNS 领域在神经刺激市场的扩张。

帕金森氏症领域预计在预测期内复合年增长率最高

由于使用植入设备来缓解症状，预计帕金森氏症领域在预测期内的复合年增长率最高。治疗帕金森氏症的神经刺激称为深部脑部刺激 (DBS)，涉及在特定大脑区域植入电极以纠正异常神经活动。 DBS 可改善患者的生活品质、减少药物依赖性并减少运动症状。因此，DBS也为神经刺激技术的发展和进步做出了重大贡献，支持了该领域的扩展。

占有率最大的地区

由于其医疗基础设施、报销政策和法律规范，亚太地区在预测期内占据了最大的市场占有率。人口高龄化以及随之而来的神经退化性疾病的增加导致对神经刺激疗法的需求不断增长。该地区的主要企业包括波士顿科学公司、雅培实验室、美敦力公司和 Neuronetics, Inc.。该地区的贷款和还款政策以及新技术正在推动市场规模的成长。

复合年增长率最高的地区：

预计欧洲在预测期内的复合年增长率最高。监管机构和国家卫生当局在核准和监管神经刺激设备方面发挥重要作用。治疗效果和患者结果的进步包括增强的电极设计、精确定位和先进的程式功能。德国、英国和法国等欧洲国家也为引进神经病变的最尖端科技做出了重大贡献，并正在推动该地区的成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球神经刺激市场：依类型

  • 荐骨神经刺激器
  • 脊髓刺激设备
  • 迷走神经刺激设备
  • 深层脑部刺激器
  • 其他类型

第六章全球神经刺激市场：依应用分类

  • 听力损失
  • 尿失禁
  • 疼痛管理
  • 癫痫
  • 帕金森氏症
  • 其他用途

第七章全球神经刺激市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第八章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第九章 公司简介

  • Medtronic
  • LivaNova PLC
  • Abbott
  • Neuronetics
  • Boston Scientific Corporation
  • Nevro Corp
  • LABORIE
  • Johnson & Johnson Services
  • NeuroPace, Inc.
  • Synapse Biomedical Inc
  • NeuroSigma, Inc
  • Modulus, Inc
  • Biegler GmbH
Product Code: SMRC24470

According to Stratistics MRC, the Global Neurostimulation Market is accounted for $6,221.2 million in 2023 and is expected to reach $13,329.0 million by 2030 growing at a CAGR of 11.5% during the forecast period. The use of regulated electrical or magnetic impulses to alter the nervous system's activity is known as neurostimulation. It is used to treat various neurological disorders such as psychiatric disorders, movement disorders, and chronic pain. Furthermore, neurostimulation is a potentially reversible and customizable method of modulating neural circuitry and relieving symptoms associated, with ongoing research exploring new applications and optimizing existing technologies.

According to Centers for Disease Control and Prevention (CDC), an estimated USD 50 billion are spent each year for treatment of chronic lower back pain in North America.

Market Dynamics:

Driver:

Increase in non-invasive alternatives

The development of non-invasive neurostimulation methods and their increasing acceptance as a result of technological advancements like transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS) which offer non-surgical approaches, reducing patient reluctance and expanding the market reach. This shift not only improve patient comfort and safety but also provide efficient, affordable, and minimally invasive solutions which place them in a position to play a significant role in influencing the direction of neurostimulation therapy, which are driving the market size.

Restraint:

High cost

Neurostimulation device development, manufacture, and distribution are expensive processes that require sophisticated technology, a great deal of research, and adherence to regulations. Specialized parts, cutting-edge materials, and complex manufacturing techniques all contribute to the higher expenses. In terms of affordability and reimbursement, these exorbitant cost present difficulties for patients and healthcare providers. Therefore, high out-of-pocket costs and a lack of insurance coverage may impede neurostimulation market.

Opportunity:

Technological advancements

Technological innovations have facilitated the development of closed-loop or adaptive neurostimulation systems with constant innovations including electrode technologies, programming capabilities, and device design which improves the accuracy, effectiveness, and safety of neurostimulation treatments. In addition, integration of wireless communication technologies enables better patient monitoring and real-time adjustments to neurostimulation parameters. By improving patient outcomes and addressing unmet medical needs overall propels the neurostimulation market.

Threat:

Side effects

Neurostimulation may not be equally effective for all neurological conditions which effects patient safety and confidence by the inherent risks associated with invasive procedures and implantable devices, which include infection, malfunctioning of the device, and unintended side effects. Moreover, adverse events can damage a product's reputation in the market and prevent its widespread adoption by giving rise to regulatory worries and legal issues. Thus, consequently hinder the neurostimulation market.

COVID-19 Impact

The COVID-19 pandemic has negatively impacted the neurostimulation market, causing disruptions in manufacturing, supply chains, and elective medical procedures. Restrictions on non-essential healthcare services, reduced patient visits, and diverted healthcare resources have led to delays in neurostimulation device implantations and decreased patient access. Economic uncertainties have also affected investment and research funding. Therefore, these factors significantly impede market expansion.

The vagus nerve stimulators segment is expected to be the largest during the forecast period

The vagus nerve stimulators segment is estimated to hold the largest share. These implantable devices stimulate the vagus nerve, which operates by sending electrical impulses to the brain. Technological advancements, miniaturization of devices, and improved understanding of neurophysiology are some of the innovations contributing awareness. The demand for non-pharmacological treatment options and the increasing prevalence of neurological disorders contribute to the expansion of the VNS segment in the Neurostimulation market.

The parkinson's disease segment is expected to have the highest CAGR during the forecast period

The parkinson's disease segment is anticipated to have the highest CAGR during the forecast period due to reducing symptoms by using implantable devices. Neurostimulation for Parkinson's disease is called deep brain stimulation (DBS), which involves implanting electrodes in particular brain areas to modify aberrant neural activity. The patients' quality of life is improved, medication dependence is decreased, and motor symptoms are reduced with DBS. Hence, it also makes a substantial contribution to the development and advancement of neurostimulation technologies which are propelling this segment expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to evaluations of the healthcare infrastructure, reimbursement policies, and regulatory frameworks. The aging population and the subsequent increase in neurodegenerative diseases contribute to the expanding demand for neurostimulation therapies. The region is home to major key players such as Boston Scientific Corporation, Abbott Laboratories, Medtronic plc and Neuronetics, Inc. The region's financing and reimbursement policies and new technologies is driving the market size.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period. Regulatory bodies and national health authorities play a crucial role in approving and regulating neurostimulation devices. Advancements in treatment efficacy and patient outcomes include enhanced electrode designs, precise targeting, and advanced programming capabilities. Countries within Europe, including Germany, the United Kingdom, France, and others, also contribute significantly to the adoption of cutting-edge technologies for neurological disorders which thereby driving region growth.

Key players in the market:

Some of the key players in the Neurostimulation Market include Medtronic, LivaNa PLC, Abbott, Neuronetics, Boston Scientific Corporation, Nevro Corp, Laborie, Johnson & Johnson Services, NeuroPace, Inc., Synapse Biomedical Inc, NeuroSigma, Inc, Modulus, Inc and Biegler GmbH.

Key Developments:

In October 2023, Boston Scientific Corporation announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter Alpha™ Spinal Cord Stimulator (SCS) Systems for the treatment of painful diabetic peripheral neuropathy (DPN), a complication of diabetes that can affect the lower extremities of the body.

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

In August 2023, Medtronic announced the outcome of the U.S. Food & Drug Administration (FDA) Circulatory System Devices Panel (CSDP) meeting to review data presented in support of the Medtronic Symplicity Spyral™ Renal Denervation (RDN) System.

In June 2023, the American Diabetes Association® (ADA) and Abbott announced a collaboration aimed at better understanding how diabetes technology like continuous glucose monitoring (CGM) systems can help people living with diabetes make informed decisions about their food and activity.

Types Covered:

  • Sacral Nerve Stimulators
  • Spinal Cord Stimulators
  • Vagus Nerve Stimulators
  • Deep Brain Stimulators
  • Other Types

Applications Covered:

  • Hearing Loss
  • Urinary Incontinence
  • Pain Management
  • Epilepsy
  • Parkinson's disease
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neurostimulation Market, By Type

  • 5.1 Introduction
  • 5.2 Sacral Nerve Stimulators
  • 5.3 Spinal Cord Stimulators
  • 5.4 Vagus Nerve Stimulators
  • 5.5 Deep Brain Stimulators
  • 5.6 Other Types

6 Global Neurostimulation Market, By Application

  • 6.1 Introduction
  • 6.2 Hearing Loss
  • 6.3 Urinary Incontinence
  • 6.4 Pain Management
  • 6.5 Epilepsy
  • 6.6 Parkinson's disease
  • 6.7 Other Applications

7 Global Neurostimulation Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Medtronic
  • 9.2 LivaNova PLC
  • 9.3 Abbott
  • 9.4 Neuronetics
  • 9.5 Boston Scientific Corporation
  • 9.6 Nevro Corp
  • 9.7 LABORIE
  • 9.8 Johnson & Johnson Services
  • 9.9 NeuroPace, Inc.
  • 9.10 Synapse Biomedical Inc
  • 9.11 NeuroSigma, Inc
  • 9.12 Modulus, Inc
  • 9.13 Biegler GmbH

List of Tables

  • Table 1 Global Neurostimulation Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neurostimulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Neurostimulation Market Outlook, By Sacral Nerve Stimulators (2021-2030) ($MN)
  • Table 4 Global Neurostimulation Market Outlook, By Spinal Cord Stimulators (2021-2030) ($MN)
  • Table 5 Global Neurostimulation Market Outlook, By Vagus Nerve Stimulators (2021-2030) ($MN)
  • Table 6 Global Neurostimulation Market Outlook, By Deep Brain Stimulators (2021-2030) ($MN)
  • Table 7 Global Neurostimulation Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Neurostimulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 9 Global Neurostimulation Market Outlook, By Hearing Loss (2021-2030) ($MN)
  • Table 10 Global Neurostimulation Market Outlook, By Urinary Incontinence (2021-2030) ($MN)
  • Table 11 Global Neurostimulation Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 12 Global Neurostimulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 13 Global Neurostimulation Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 14 Global Neurostimulation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 15 North America Neurostimulation Market Outlook, By Country (2021-2030) ($MN)
  • Table 16 North America Neurostimulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 17 North America Neurostimulation Market Outlook, By Sacral Nerve Stimulators (2021-2030) ($MN)
  • Table 18 North America Neurostimulation Market Outlook, By Spinal Cord Stimulators (2021-2030) ($MN)
  • Table 19 North America Neurostimulation Market Outlook, By Vagus Nerve Stimulators (2021-2030) ($MN)
  • Table 20 North America Neurostimulation Market Outlook, By Deep Brain Stimulators (2021-2030) ($MN)
  • Table 21 North America Neurostimulation Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 22 North America Neurostimulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 23 North America Neurostimulation Market Outlook, By Hearing Loss (2021-2030) ($MN)
  • Table 24 North America Neurostimulation Market Outlook, By Urinary Incontinence (2021-2030) ($MN)
  • Table 25 North America Neurostimulation Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 26 North America Neurostimulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 27 North America Neurostimulation Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 28 North America Neurostimulation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 29 Europe Neurostimulation Market Outlook, By Country (2021-2030) ($MN)
  • Table 30 Europe Neurostimulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 31 Europe Neurostimulation Market Outlook, By Sacral Nerve Stimulators (2021-2030) ($MN)
  • Table 32 Europe Neurostimulation Market Outlook, By Spinal Cord Stimulators (2021-2030) ($MN)
  • Table 33 Europe Neurostimulation Market Outlook, By Vagus Nerve Stimulators (2021-2030) ($MN)
  • Table 34 Europe Neurostimulation Market Outlook, By Deep Brain Stimulators (2021-2030) ($MN)
  • Table 35 Europe Neurostimulation Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 36 Europe Neurostimulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 37 Europe Neurostimulation Market Outlook, By Hearing Loss (2021-2030) ($MN)
  • Table 38 Europe Neurostimulation Market Outlook, By Urinary Incontinence (2021-2030) ($MN)
  • Table 39 Europe Neurostimulation Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 40 Europe Neurostimulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 41 Europe Neurostimulation Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 42 Europe Neurostimulation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 43 Asia Pacific Neurostimulation Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Asia Pacific Neurostimulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 45 Asia Pacific Neurostimulation Market Outlook, By Sacral Nerve Stimulators (2021-2030) ($MN)
  • Table 46 Asia Pacific Neurostimulation Market Outlook, By Spinal Cord Stimulators (2021-2030) ($MN)
  • Table 47 Asia Pacific Neurostimulation Market Outlook, By Vagus Nerve Stimulators (2021-2030) ($MN)
  • Table 48 Asia Pacific Neurostimulation Market Outlook, By Deep Brain Stimulators (2021-2030) ($MN)
  • Table 49 Asia Pacific Neurostimulation Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 50 Asia Pacific Neurostimulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 51 Asia Pacific Neurostimulation Market Outlook, By Hearing Loss (2021-2030) ($MN)
  • Table 52 Asia Pacific Neurostimulation Market Outlook, By Urinary Incontinence (2021-2030) ($MN)
  • Table 53 Asia Pacific Neurostimulation Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 54 Asia Pacific Neurostimulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 55 Asia Pacific Neurostimulation Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 56 Asia Pacific Neurostimulation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 57 South America Neurostimulation Market Outlook, By Country (2021-2030) ($MN)
  • Table 58 South America Neurostimulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 59 South America Neurostimulation Market Outlook, By Sacral Nerve Stimulators (2021-2030) ($MN)
  • Table 60 South America Neurostimulation Market Outlook, By Spinal Cord Stimulators (2021-2030) ($MN)
  • Table 61 South America Neurostimulation Market Outlook, By Vagus Nerve Stimulators (2021-2030) ($MN)
  • Table 62 South America Neurostimulation Market Outlook, By Deep Brain Stimulators (2021-2030) ($MN)
  • Table 63 South America Neurostimulation Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 64 South America Neurostimulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 65 South America Neurostimulation Market Outlook, By Hearing Loss (2021-2030) ($MN)
  • Table 66 South America Neurostimulation Market Outlook, By Urinary Incontinence (2021-2030) ($MN)
  • Table 67 South America Neurostimulation Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 68 South America Neurostimulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 69 South America Neurostimulation Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 70 South America Neurostimulation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 71 Middle East & Africa Neurostimulation Market Outlook, By Country (2021-2030) ($MN)
  • Table 72 Middle East & Africa Neurostimulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 73 Middle East & Africa Neurostimulation Market Outlook, By Sacral Nerve Stimulators (2021-2030) ($MN)
  • Table 74 Middle East & Africa Neurostimulation Market Outlook, By Spinal Cord Stimulators (2021-2030) ($MN)
  • Table 75 Middle East & Africa Neurostimulation Market Outlook, By Vagus Nerve Stimulators (2021-2030) ($MN)
  • Table 76 Middle East & Africa Neurostimulation Market Outlook, By Deep Brain Stimulators (2021-2030) ($MN)
  • Table 77 Middle East & Africa Neurostimulation Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 78 Middle East & Africa Neurostimulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 79 Middle East & Africa Neurostimulation Market Outlook, By Hearing Loss (2021-2030) ($MN)
  • Table 80 Middle East & Africa Neurostimulation Market Outlook, By Urinary Incontinence (2021-2030) ($MN)
  • Table 81 Middle East & Africa Neurostimulation Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 82 Middle East & Africa Neurostimulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 83 Middle East & Africa Neurostimulation Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 84 Middle East & Africa Neurostimulation Market Outlook, By Other Applications (2021-2030) ($MN)